| Customization: | Available |
|---|---|
| Dosage Form: | Injection |
| Dossier: | Ready |
|
Still deciding? Get samples of US$ 0.1/Piece
Request Sample
|
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
| Generic Name | Gentamycin BP Injection 80mg/2ml |
| Strength | 80mg/2ml |
| Packing | 10ampoules/box |
| Origin | China |
This product is colorless or almost colorless clear liquid.
1. It is suitable for the treatment of serious infections caused by sensitive gram-negative bacteria, such as Escherichia coli, Klebsiella, Enterobacter, Proteus, Serrella, Pseudomonas aeruginosa and methicillin-sensitive strains of Staphylococcus, such as sepsis, lower respiratory tract infection, intestinal infection, pelvic infection, abdominal infection, skin soft tissue infection, complex urinary tract infection, etc. In combination with penicillin (or ampicillin), enterococcal infections are treated.
2. For central nervous system infection caused by sensitive bacteria, such as meningitis and ventriculitis, intrathecal injection of this product can be used as auxiliary treatment at the same time.
Usage and dosage:
1: Adults
Intramuscular injection or intravenous infusion after dilution, 80mg(80,000 units) once, or 1 to 1.7mg/kg once per body weight, once every 8 hours; Or 5mg/kg once, once every 24 hours, the course of treatment is 7-14 days. When the intravenous drip is added to 50 ~ 200ml of 0.9% sodium chloride injection or 5% glucose injection, the amount of liquid added once a day should be not less than 300ml, so that the concentration of the liquid does not exceed 0.1%, the solution should be slowly dropped within 30 ~ 60 minutes to avoid neuromuscular block.
2. Children
Intramuscular injection or intravenous infusion after dilution, once 2.5mg/kg, once every 12 hours; Or 1.7mg/kg once every 8 hours. The course of treatment is 7 to 14 days, during which blood concentration should be monitored as much as possible, especially in newborns or infants.
3. Intrathecal and intraventricular administration
The dosage is 4 to 8mg once for adults and 1 to 2mg once for children (over 3 months), once every 2 to 3 days. During the injection, the liquid was diluted to a concentration of no more than 0.2%, and pumped into a 5ml or 10ml sterile syringe. After the lumbar puncture, a considerable amount of cerebrospinal fluid was injected into the syringe, and all the liquid was injected slowly within 3 to 5 minutes.
4. Dosage for patients with renal dysfunction
According to normal renal function once every 8 hours, the normal dose of one time is 1 ~ 1.7mg/kg, creatinine clearance rate is 10 ~ 50ml/min, once every 12 hours, once is 30% ~ 70% of the normal dose; Creatinine clearance < At 10ml/min, 20% to 30% of the normal dose is given every 24 to 48 hours.
Creatinine clearance can be measured directly or calculated from the patient's blood creatinine value as follows:
Adult male creatinine clearance = (140- age) × standard body weight (kg)/ 72× patient's blood creatinine concentration (mg/dl)
Or = (140-age) × standard body weight (kg)/ 50× patient's blood creatinine concentration (u mol/L)
Adult female creatinine clearance =0.85× (140-age) × standard body weight (kg)/ 72× patient's blood creatinine concentration (mg/dl)
Or =0.85× (140-age) × standard body weight (kg)/ 50× patient's blood creatinine concentration (u mol/L)
5. After hemodialysis, according to the severity of infection, adults can be supplied with 1 to 1.7mg/kg per body weight, and children (more than 3 months) can be supplied with 2 to 2.5mg/kg. Above) a supply of 2 ~ 2.5mg/kg.
Matters needing attention:
1. This product should be used with caution in the following situations: water loss, No. 8 patients with cranial nerve damage, myasthenia gravis or Parkinson's disease and renal function damage.
3. Routine urine and renal function tests should be performed regularly before and during medication to prevent severe nephrotoxic reactions. If necessary, a hearing examination or electroaudiogram, especially a high-frequency audiometry, and a temperature stimulation test, are performed to detect vestibular toxicity.
4. If conditions permit, the blood concentration should be monitored during the course of treatment, and the dose should be adjusted according to it, especially for newborns, the elderly and patients with renal dysfunction. The effective blood concentration should be maintained at 4-10 μg/ml, the peak concentration should be avoided to exceed 12μg/ml, and the trough concentration should be maintained at 1-2 μg/ml. The peak blood concentration should be maintained at 16-24 μg/ml, and the trough concentration should be <. 1μg/ml. Patients receiving intrathecal injection should also monitor the concentration of drugs in the cerebrospinal fluid.
5. When the blood concentration cannot be determined, the dose should be adjusted according to the measured creatinine clearance.
6. After the first saturated dose (1 to 2mg/kg), maintenance should be reduced in patients with renal insufficiency, vestibular function, or hearing loss.
7. Patients should be given enough water to reduce damage to the renal tubules.
8. Long-term application may lead to excessive growth of drug-resistant bacteria.
9. Not suitable for subcutaneous injection.
10. This product has respiratory inhibiting effect and should not be injected intravenously.
11. Interference with diagnosis: This product can increase the determination values of alanine aminotransferase (ALT), aspartate aminotransferase (GOT), serum bilirubin concentration and lactate dehydrogenase concentration; The concentrations of calcium, magnesium, potassium and sodium in the blood may be decreased.
){kind=link}